Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis
Matye D, Wang H, Luo W, Sharp R, Chen C, Gu L, Jones K, Ding W, Friedman J, Li T. Combined ASBT Inhibitor and FGF15 Treatment Improves Therapeutic Efficacy in Experimental Nonalcoholic Steatohepatitis. Cellular And Molecular Gastroenterology And Hepatology 2021, 12: 1001-1019. PMID: 33965587, PMCID: PMC8346663, DOI: 10.1016/j.jcmgh.2021.04.013.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBile Acids and SaltsCholesterolCombined Modality TherapyDependovirusDisease Models, AnimalFibroblast Growth FactorsFructoseGene Expression ProfilingGene Expression RegulationGenetic TherapyGenetic VectorsMaleMethylaminesMiceNon-alcoholic Fatty Liver DiseaseThiazepinesTreatment OutcomeConceptsNonalcoholic steatohepatitisBile acid synthesisTherapeutic efficacyFGF19 analogueASBT inhibitorTreatment-associated adverse eventsFecal bile acid excretionASBT inhibitionDiet-induced nonalcoholic steatohepatitisHepatic bile acid synthesisWeight lossBile acid excretionGrowth factor 15Experimental nonalcoholic steatohepatitisDiet-fed miceFurther clinical studiesNew treatment strategiesIntestinal lipid absorptionAdverse eventsAdipose inflammationMetabolic improvementTreatment attenuatesLipid malabsorptionClinical findingsTreatment strategies